The Clinical Investigations Support Office (CISO) serves as a centralized unit to oversee the clinical research infrastructure and assist investigators in their conduct of clinical trials and translational research projects. CISO has been reorganized following recommendations of an external advisory group and the Cancer Center Executive Committee and with the concurrence of the NCCC External Advisory Committee. The 58 personnel are now located in 15 of newly remodeled contiguous offices in the Ezralow Tower of the Cancer Center. CISO has three main operational units: 1) Protocol Administration;2) Protocol Implementation;and 3) Administrative/Business Management. The Protocol Administration Unit provides the centralized consultation and regulatory services necessary for the design, initiation, and conduct of externally-funded and internally peer-reviewed and monitored clinical trials. The Protocol Implementation Unit provides the centralized function of advising and assisting investigators in patient eligibility assessments, patient recruitment, data quality control and oversight. The Administrative/Business Management Unit was recently created in 2007 in order to coordinate CISO's relationships with institutional entities outside the Cancer Center and with sponsors. It is also charged with assisting the various investigators and sections to manage their funding sources, allocate their financial and human resources in an efficient manner, and be able to make sound projections for future growth. In addition to the services provided by the three operational units, CISO plays a central coordinating role within the Cancer Center through its interactions with other cores such as the Biostatistics Core, the Cancer Research Informatics Core (CRIC), the Translational Pathology Core, and the Protocol Review and Monitoring System entities (Clinical Investigations Committee and the Quality Assurance and Monitoring Committee). The Cancer Center Executive Committee exercises full authority over CISO policies and resource allocation and reviews the CISO's performance on a biannual basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-39
Application #
8589359
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$392,416
Indirect Cost
$142,794
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Thomas, Duncan C (2017) Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer. Epidemiology 28:470-478
Thomas, Duncan C (2017) What Does ""Precision Medicine"" Have to Say About Prevention? Epidemiology 28:479-483
Bensman, Timothy J; Jayne, Jordanna G; Sun, Meiling et al. (2017) Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother 61:
Okazaki, Satoshi; Stintzing, Sebastian; Sunakawa, Yu et al. (2017) Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer 141:1222-1230
Liang, Gangning; Weisenberger, Daniel J (2017) DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics 12:416-432
Schwitzer, Emily; Orlow, Irene; Zabor, Emily C et al. (2017) No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. Pigment Cell Melanoma Res 30:424-427
Reid, Brett M; Permuth, Jennifer B; Chen, Y Ann et al. (2017) Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 26:116-125
Poulard, Coralie; Bittencourt, Danielle; Wu, Dai-Ying et al. (2017) A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP. EMBO Rep 18:1442-1459
Kim, Yong-Mi; Gang, Eun-Ji; Kahn, Michael (2017) CBP/Catenin antagonists: Targeting LSCs' Achilles heel. Exp Hematol 52:1-11
Qi, D-L; Cobrinik, D (2017) MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation. Oncogene 36:1760-1769

Showing the most recent 10 out of 739 publications